-
FDA sets May 2027 decision date on AMT-130 gene therapy for HD
4 min read
Latest News
-
October 2026: This Month in Huntington’s Disease Research
4 min read
From sticky thoughts and pigs that model HD to DNA repair and promising drug trial results, October brought fresh insights into HD. Here’s what you might have missed!
-
The genetic 'gray area' of Huntington's disease: what does it all mean?
8 min read
Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained
-
Dimebon fails in late-stage human HD clinical trial
3 min read
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
-
FDA: further trial needed for Huntexil approval in HD
2 min read
Bad news for Huntexil – the FDA requires another trial before it can be approved in the US
-
Successful gene therapy trial in Parkinson’s Disease gives hope for HD
5 min read
Success for brain ‘gene therapy’ in Parkinson’s disease – good news for similar treatments being developed in HD
-
Gene silencing for HD: the story so far
10 min read
Is gene silencing as exciting as it sounds for HD, and what might the future hold?
-
Interview: Graeme Bilbe, Global Head for Neuroscience at Novartis
7 min read
HDBuzz interviews Graeme Bilbe, Global Head for Neuroscience at pharmaceutical giant Novartis, about their HD researc
-
What do sheep brains have to do with HD?
7 min read
How smart are sheep, and why do HD researchers care?
-
Interview: CHDI Management
11 min read
HDBuzz interviews three top scientists from CHDI, the biggest funder and driver of HD research worldwide
-
CHDI Report: Day 3
8 min read
Day 3 of CHDI’s HD therapeutics conference: growth factors and CHDI’s advanced therapies
-
CHDI Report: Day 2
5 min read
Day 2 of CHDI’s HD therapeutics conference: figuring out energy problems in HD
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
